Pharmaceutical companies cannot effectively deliver drugs across the blood-brain barrier to treat neurological diseases

Pharma companies struggle to transport therapeutic drugs across the blood-brain barrier (BBB), a critical biological obstacle that blocks most drug molecules from reaching the brain and central nervous system. This failure results in abandoned neuroscience pipelines, failed clinical trials, and inability to treat neurological disorders like Alzheimer's, Parkinson's, and brain tumors. Current delivery methods are ineffective, forcing companies to acquire specialized platform technologies at premium prices ($125M+) just to solve this single technical bottleneck.